Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen

Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed extensive-stage small cell lung cancer (SCLC). The collaboration is aimed to evaluate safety, tolerability and efficacy of Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) in combination with AbbVie’s investigational biomarker-specific antibody drug Rova-T (rovalpituuzumab tesirine) in a phase I/II clinical trial,. The combination will be tested to promote targeted cell killing and antigen release with an enhanced immunotherapy effect.

BioLineRx’s collaboration with MD Anderson Cancer Centre, Texas is set to assess the effectiveness of 2 Immunotherapies

BioLineRx is set to investigate how it’s new drug candidate, BL-8040, interacts with Keytruda (pembrolizumab), Merck’s blockbuster drug. The study will be conducted as a investigator-sponsored study, and would be a part of the clinical research that is being conducted by Merck and MD Anderson Cancer Center, as they are involved in a clinical research collaboration for studying the effect of Keytruda in combination with several other drugs and treatments. The open label Phase 2 study is expected to start later this year.

Partnership between Regeneron Pharmaceuticals and Adicet Bio may result in new treatment options for certain Cancers

A strategic collaboration and licensing agreement between Regeneron Pharmaceuticals and Adicet Bio is set to develop immune cell therapeutics like CAR T cell and TCR in several hematological and solid tumors. These companies have shared that the collaboration aims to access and improve the therapy for eliminating solid tumors through Adicet’s cell platform now under development, and innovative targeting approaches. Adicet is expected to pay an upfront payment of $25 million to Regeneron, as well as research funding over five years.

Immunotherapy Targeting Unique Mutations in a Cancer to be developed through Alliance between Amgen and Advaxis

Partnership between Amgen and Advaxis will lead to the development and commercialization of Advaxis’ Adxs-Neo, which is a potential cancer immunotherapy. This therapy is right now in its preclinical development stage. This alliance benefits from the expertise Amgen has in immuno-oncology, and Advaxis’ MINE (My Immunotherapy Neo-Epitopes) program. The MINE platform is designed to activate the immune system of the patient to respond against unique mutations present in the tumor. They will also make an upfront payment of $40 million to Advaxis, and will also purchase $25 million of Advaxis common stock. Apart from that, Amgen is said to take responsibility of funding clinical and commercial activities. Advaxis will also receive development, regulatory and sales milestone payments of up to $475 million, and will develop the Adxs-Neo through proof of concept studies.